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In this issue, Berggren et al. [1] provide a useful com-
parative summary of 25 current pharmacoeconomic
guidelines from Europe, North America, and Austra-
lia. One can look at these guidelines as reflecting ma-
jor progress since Australia first promulgated formal
methodological standards for economic evaluation of
pharmaceuticals in 1992. Berggren et al. [1] find that
there is substantial consensus on many issues of meth-
odology, including target audience, preferred out-
come measurement, type of analysis, treatment com-
parators, acceptable data sources, use of modeling,
time horizon, sensitivity analysis, and results report-
ing. Pharmacoeconomics has come of age in being
able to point to a body of generally accepted methods,
techniques, and practices. This is certainly good news.
The areas with less harmonization include choice
of study perspective, resources and costs to be in-
cluded in the analysis (particularly the treatment of in-
formal costs), and method of pricing resources used. It
isn’t surprising that type and price of resources evalu-
ated would exhibit discordance, since most differences
here flow directly from differences in the study per-
spective chosen. Most of the guidelines acknowledge
the value of a societal perspective for pharmacoeco-
nomic analyses, but some guidelines require a nar-
rower health plan or government perspective, rather
than a societal one.
It has never been clear to me precisely what the
 
third-party payer/government perspective is (or
should be), and how it specifically differs from the
societal perspective. While patient health outcomes
ought to have value to a government or third-party
payer, how should these organizations weigh such
benefits? For example, consider a drug intervention
(e.g., diabetes control, lipid control, or hyperten-
sion control) that takes several years of treatment
to become “cost-effective” when analyzed from a
societal perspective. A government looking to bal-
ance its fiscal budget before the next election, or a
managed care organization looking to maximize its
stockholder equity value this quarter, might con-
sider a time horizon or a high discount rate that tips
the cost-effectiveness scales against such an inter-
vention. Even worse, a managed care organization
in a competitive market environment might hope
that such chronic disease patients switch to another
health plan precisely because they prefer to refuse
to pay for the medication in question. Coverage
and formulary decisions can be used to “squeeze
the lemons,” getting high-risk patients to drop out
of the plan altogether. And when a government re-
fuses to pay for such a medication, its covered pa-
tients generally have no choice in the matter.
One could argue that an enlightened govern-
ment or managed care organization would never
take such a short-term perspective, but are all real-
world health care purchasers so enlightened? What
ethical obligation do pharmacoeconomic research-
ers have in ensuring that the perspective chosen for
a study is consistent with fair and efficient alloca-
tion of society’s health care resources?
Health economists generally advocate the societal
perspective [2,3]. In addition to encouraging appro-
priate societal health care resource allocation, this
promotes standardization of reported results, so that
the cost-effectiveness of different treatments can be
handily compared across different studies. In any spe-
cific context, it certainly may be valuable and useful to
also describe the costs and outcomes of a medical in-
tervention from narrower perspectives, but only when
the societal reference case perspective is also provided.
Convincing all pharmacoeconomic guideline develop-
ers to adopt such a position would go a long way to-
ward ensuring global guideline consensus.
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